Fans in the US and Canada will get manga faster, and the company plans to expand the app's digital library. Kourtnee covers TV streaming services and home entertainment. She previously worked as an ...

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data demonstrating how the Viz HCM module enables ...

Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook Viz Media has announced they will be launching a new digital manga service bringing even more ...

The startup has 12 FDA-approved algorithms to flag problems, agreements with more than 1,500 U.S. hospitals, and big plans to work with drug companies to reduce roadblocks in healthcare. On October 26 ...

Viz Media has launched a new app and subscription service, allow fans to read their favorite manga digitally. Viz Manga will cost $1.99 a month, and the service will give fans access to over 10,000 ...

Humans are visual creatures, and today, when the national conversation is framed by data-driven topics like climate change, data security, and gerrymandering, data visualization has never been more ...

Rei is an Editor for GameRant's Evergreen and Features teams from Kashmir, situated in Beirut. He's an avid fan of anime, manga, and gaming. He is the author of some of the articles here that you ...

The mission of VIZ Originals, American manga publisher Viz Media’s newest imprint, is to deliver original manga-inspired graphic novels and manga adaptations of popular stories from books, television, ...

Viz.ai is already an old hand at putting its disease-spotting artificial intelligence algorithms through the FDA review process, having secured the agency’s sign-off for seven of the AI tools to date.

The subscription price to Viz Media’s digital Weekly Shonen Jump library is going to go up very soon following an announcement shared with fans. Viz Media has been offering the latest chapters from ...

The U.S. Food and Drug Administration's approval of Viz.ai's hypertrophic cardiomyopathy establishes a new category for cardiovascular machine learning-based notification software. Viz.ai, a disease ...